• Explore /
  • Poster
  • / Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).

Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).

Abstract Poster

Authors

Eric Small

Eric Jay Small

University of California, San Francisco, San Francisco, CA

Eric Jay Small , Raymond S. Lance , Charles H. Redfern , Frederick E. Millard , Thomas A. Gardner , Nancy Ann Dawson , Lawrence Fong , Lawrence Ivan Karsh , John M. Corman , Luke T. Nordquist , Myron I Murdock , Brendan D. Curti , Nancy N. Chang , Neal D. Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01487863

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 190)

DOI

10.1200/JCO.2017.35.6_suppl.190

Abstract #

190

Poster Bd #

G19

Abstract Disclosures

Similar Posters

First Author: Celestia S. Higano

First Author: David Johnson Einstein

First Author: Daniel Peter Petrylak

First Author: Sumit Kumar Subudhi